^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Bayer Press Release
    Title:

    Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's Lymphoma

    Published date:
    10/14/2020
    Excerpt:
    Bayer today announced that the Phase III study CHRONOS-3 evaluating copanlisib in combination with rituximab in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL), which included patients with follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma and lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia, has met its primary endpoint of significantly prolonging progression-free survival (PFS).
    Trial ID:
    CHRONOS-3